Research programme: candidiasis therapeutics - Bionex Pharmaceuticals/University of Medicine & Dentistry of New Jersey

Drug Profile

Research programme: candidiasis therapeutics - Bionex Pharmaceuticals/University of Medicine & Dentistry of New Jersey

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator Bionex Pharmaceuticals
  • Developer Bionex Pharmaceuticals; University of Medicine & Dentistry of New Jersey
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Candidiasis

Most Recent Events

  • 15 Nov 2016 Early research in Candidiasis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top